Skip to main content
Ipsen logo

Ipsen — Investor Relations & Filings

Ticker · IPN ISIN · FR0010259150 LEI · 549300M6SGDPB4Z94P11 PA Manufacturing
Open in API
Filings indexed 1,378 across all filing types
Latest filing 2022-08-02 Transaction in Own Shar…
Country FR France
Listing PA IPN

About Ipsen

https://www.ipsen.com/

Ipsen is a global biopharmaceutical company focused on innovation and specialty care. The company develops and commercializes transformative medicines to address high unmet medical needs in three key therapeutic areas: oncology, rare diseases, and neuroscience. By leveraging its specialized expertise and strategic partnerships, Ipsen aims to accelerate the development of new therapies and improve health outcomes for patients worldwide. Its strategy is centered on advancing science with purpose to bring innovative treatments from research and development to the market.

Recent filings

Filing Released Lang Actions
Acquisition ou cession des actions de l'émetteur / Transactions sur actions propres (version agrégée)
Transaction in Own Shares Classification · 1% confidence The document title is "Déclaration des transactions sur actions propres réalisées du 25 au 29 Juillet 2022" (Declaration of transactions on own shares carried out from July 25 to 29, 2022). The content is a table detailing the volume and average price of shares transacted by the issuer (IPSEN) on specific dates. This directly corresponds to the definition of a report detailing the company buying back or selling its own shares, which is classified as 'Transaction in Own Shares' (POS). The document is not a short announcement linking to a report, but the report itself detailing the transactions.
2022-08-02 French
Acquisition or disposal of the issuer's own shares / Transaction in own shares (aggregate version)
Transaction in Own Shares Classification · 1% confidence The document explicitly details a 'Disclosure transaction in own shares' occurring between specific dates (25/07/2022 to 29/07/2022). It provides a table showing the daily volume, weighted average price, and platform for these transactions. This content directly matches the definition for 'Transaction in Own Shares' (Code: POS), which covers company share repurchases or issuance.
2022-08-02 English
Inside Information / Operations of the issuer (acquisitions, sales...)
Capital/Financing Update Classification · 1% confidence The document is a press release announcing a strategic partnership between two companies, Ipsen and Marengo Therapeutics, regarding the advancement of immuno-oncology candidates. It details financial terms (upfront payment, milestones, royalties), outlines responsibilities for preclinical and clinical development, and includes standard sections like 'About Ipsen', 'About Marengo Therapeutics', and 'Forward-Looking Statements'. This type of announcement, detailing a significant business transaction (collaboration/deal) involving financing and future development rights, most closely aligns with a Capital/Financing Update (CAP) or potentially a Regulatory Filing (RNS) if it were a mandatory disclosure. However, given the focus on the financial structure of the deal (\$45 million upfront, potential \$1.592 billion milestones) and the strategic nature of the collaboration, 'Capital/Financing Update' (CAP) is the most specific fit among the provided options for a major business development announcement involving significant financial consideration.
2022-08-01 English
Informations privilégiées / Opérations de l'émetteur (acquisitions, cessions...)
Capital/Financing Update Classification · 1% confidence The document is a press release dated August 1, 2022, announcing a strategic partnership between Ipsen and Marengo Therapeutics regarding the development of immuno-oncology treatments. It details financial terms (initial payment, milestones, royalties) and outlines the division of responsibilities for preclinical, clinical development, and commercialization. This type of announcement, focusing on a significant business development (a collaboration/deal) and providing key financial and strategic context, aligns best with a general corporate announcement or a specific financing/capital event if the deal involved a major upfront payment or equity component. Since it is a strategic partnership announcement detailing financial commitments and future development plans, it fits the description of 'Capital/Financing Update' (CAP) if the focus is on the funding/deal structure, or potentially 'Regulatory Filings' (RNS) if it were a mandatory disclosure. However, given the content is a detailed press release about a major business transaction involving upfront payments and potential future payments, 'Capital/Financing Update' (CAP) is a strong candidate, as it relates to capital deployment and structure changes. Alternatively, since it is a major corporate event announcement, it could also be classified as a general Regulatory Filing (RNS) if a more specific code isn't available. Comparing the definitions, 'CAP' covers 'Updates on company fundraising, financing activities, or capital structure changes.' A strategic partnership with a $45M upfront payment and $1.592B potential milestones fits 'financing activities' or 'capital structure changes' in a broad sense related to R&D funding/structure. Given the high specificity of the other codes, and the nature of the announcement being a strategic deal announcement, 'CAP' is the most appropriate fit among the options that describe business transactions, rather than a standard report (10-K, IR) or a management change (MANG). It is not an Earnings Release (ER) or a Call Transcript (CT). It is a formal announcement of a significant business transaction.
2022-08-01 French
2022 Half-year financial report
Interim / Quarterly Report Classification · 1% confidence The document contains comprehensive 2022 half-year condensed consolidated financial statements, including income statements, balance sheets, and cash flow statements. It is a formal financial report for a period shorter than a full fiscal year, which fits the definition of an Interim/Quarterly Report (IR). It is not an announcement or a summary, as it provides the full financial data tables. H2 2022
2022-07-28 English
Rapport financier semestriel 2022
Interim / Quarterly Report Classification · 1% confidence The document is a comprehensive financial report for the first half of 2022, containing consolidated financial statements (income statement, balance sheet, cash flow statement), notes, and management activity reports. It is not a short announcement or a certification, but the actual interim financial report. Therefore, it fits the definition of an Interim / Quarterly Report (IR). H1 2022
2022-07-28 French

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.